Actavis ready to leap into Big Pharma with $64B bid for Allergan

A months-long pursuit of Allergan ($AGN) may be about to come to a close for Valeant ($VRX) and activist investor Bill Ackman--but not with the results they were hoping for.

Bill Ackman

The Botox maker is close to selling itself to white knight Actavis ($ACT), which has offered to pay more than $215 per share, the Financial Times' sources say. The two companies' boards are expected to meet to review a cash-and-stock takeover, The Wall Street Journal reports, with an announcement likely coming this week.

That doesn't mean Valeant and Ackman--whose deal plans are locked up in a proxy fight--are out of the game completely. The Canadian pharma could come back with a higher bid--something it's done many times since it set out to acquire Allergan this spring.

Valeant CEO J. Michael Pearson

But according to the FT, Valeant's not about to enter a bidding war. CEO J. Michael Pearson is a "very disciplined" bidder and will keep his own shareholders in mind when weighing a higher offer, a source told the newspaper. While Pearson has said Valeant is prepared to hike its bid past $200 a share, it's unclear how much higher the serial dealmaker would be willing to go.

While Valeant has been the one touting its goal to sit among the world's top-selling drugmakers, if Actavis does land Allergan, the buyout would create a company that rakes in about $23 billion a year in sales--vaulting it near the top 10 itself, the WSJ notes.

"This is going to be a Big Pharma," Sanford C. Bernstein analyst Ronny Gal told the paper.

But Pearson's pickup machine may have a Plan B. Last week, Ackman acquired an 8.5% stake in Pfizer animal health spinoff Zoetis ($ZTS), which he may use to pressure the company to sell itself to Valeant.

- read the FT story (sub. req.)
- get more from the WSJ (sub. req.)

Special Reports: The most influential people in biopharma today - J. Michael Pearson, Valeant | 20 Highest-Paid Biopharma CEOs of 2012 - David Pyott, Allergan

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.